Association of Tumor Budding With Immune Evasion Pathways in Primary Colorectal Cancer and Patient-Derived Xenografts

doi:10.3389/fmed.2020.00264

PMC full text:

Front Med (Lausanne). 2020; 7: 264.

Published online 2020 Jul 3. doi: 10.3389/fmed.2020.00264

Copyright/LicenseRequest permission to reuse: Copyright © 2020 Guil-Luna, Mena, Navarrete-Sirvent, López-Sánchez, Khouadri, Toledano-Fonseca, Mantrana, Guler, Villar, Díaz, Medina-Fernández, De la Haba-Rodríguez, Aranda and Rodríguez-Ariza.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Table 3

Multivariate analysis of clinicopathological data of the tumors.

Variables	BD2 vs. BD1			BD3 vs. BD1
	Coef (SD)	P-value	OR 95% CI	Coef (SD)	P-value	OR 95% CI
Tumor size	−0.91 (0.46)	0.046	0.40 [0.16-0.98]	−0.73 (0.44)	0.097	0.48 [0.20–1.14]
Moderate vs. well diff.	12.33 (0.92)	<0.001	2.27 × 10⁵ [3.73 × 10⁴-1.38 × 10⁶]	1.90 (1.43)	0.184	6.72 [0.4–112.30]
Poorly vs. well diff.	23.12 (0.80)	<0.001	1.10 × 10¹⁰ [2.28 × 10⁹-5.38 × 10¹⁰]	13.66 (0.80)	<0.001	8.57 × 10⁵ [2.28 × 10⁹-5.38 × 10¹⁰]
Stromal component	0.007 (0.02)	0.772	1.007 [0.95–1.05]	0.04 (0.02)	0.055	1.04 [0.99–1.08]

Coef, coefficient; SD, standard deviation; OR, odds ratio; CI, confidence interval; BD1, budding grade 1; BD2, budding grade 2; BD3, budding grade 3.